Benzinga | Apr 30, 2021 07:21AM EDT

RBC Capital Maintains Outperform on Nurix Therapeutics, Announces $42 Price Target

RBC Capital analyst Kennen MacKay maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and announces $42 price target.